L'intérêt à découvert pour Mineralys Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Mineralys Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Mineralys Therapeutics (NASDAQ:MLYS) Stock, Rapport sur les intérêts à découvert

MINERALYS THERAPEUTICS INC

Mineralys Therapeutics

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics Inc

Maxim Group analyst Jack Vander Aarde maintains VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) with a Buy and lowers the price target from $2 to $1.5.

News

Price Target

Analyst Ratings

VRME

Maxim Group Maintains Buy on VerifyMe, Lowers Price Target to $1.5

Biodesix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) reported weaker-than-expected results for the first <a href="https://www.benzinga.com/quote/BDSX/earnings">quarter on Tuesday</a>.
The company posted quarterly losses of 8 cents per share which missed the analyst consensus estimate of losses of 7 cents per share. The company reported quarterly sales of $17.96 million which missed the analyst consensus estimate of $19.47 million.
&#8220;Our quarter was highlighted by continued progress toward our three key goals for 2025 – growing top line revenue, improving operational efficiencies and leverage, and advancing our pipeline,&#8221; said Scott Hutton, Chief Executive Officer. &#8220;Year-over-year, we grew revenue by 21%, powered by growth in both our lung diagnostic testing and diagnostic services, all while decreasing our SG&amp;A spend. Lung Diagnostics revenue grew 18%, which is the 16th straight quarter of greater than 15% growth. We also increased our already strong gross margins to 79.4%, improved Net Loss by 18% and Adjusted EBITDA by 11% on our path to profitability, and presented multiple studies on our pipeline products to help facilitate future growth.&#8221;
Biodesix lowered its FY2025 sales guidance from $92.00 million-$95.00 million to $80.00 million-$85.00 million.
Biodesix shares fell 39.3% to trade at $0.2180 on Wednesday.
These analysts made changes to their price targets on Biodesix following earnings announcement.
<ul class="wp-block-list">
<li>Lake Street analyst Thomas Flaten maintained Biodesix with a Buy and lowered the price target from $3 to $2.</li>
<li>Canaccord Genuity analyst Kyle Mikson maintained the stock with a Buy and lowered the price target from $2.5 to $1.5.</li>
<li>William Blair analyst Brian Weinstein downgraded Biodesix from Outperform to Market Perform.</li>
</ul>
Considering buying BDSX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14133022/image-168-1024x576.png" alt="" class="wp-image-915425" style="width:660px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14133022/image-168-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14133022/image-168-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14133022/image-168-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14133022/image-168.png 1080w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45403847/coinbase-to-rally-around-17-here-are-10-top-analyst-forecasts-for-wednesday">Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday</a> </li>
</ul>
Photo via Shutterstock

Earnings

BDSX

Biodesix Analysts Lower Their Forecasts After Downbeat Q1 Results

Roth MKM analyst Sean McGowan maintains Monster Beverage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) with a Neutral and raises the price target from $50 to $56.

MNST

Roth MKM Maintains Neutral on Monster Beverage, Raises Price Target to $56

WIIM

ABSI

ABSI stock has given up its prior gain. Absci shares were trading higher after the company announced it began dosing the first participants in its Phase 1 ABS-101 clinical trial.

Although talk of a recession has some investors spooked, stock market veterans like CNBC's Jim Cramer see it as an opportunity to pick up undervalued stocks. On a recent episode of<a href="https://www.cnbc.com/2025/03/13/jim-cramer-names-retail-stocks-to-buy-as-the-market-pulls-back.html"> "Mad Money</a>," Cramer discussed the economy and two stocks he believes are worth buying during any potential dip.
&nbsp;"As long as you don't think the entire economy is about to fall off a cliff, and there's still some of us who feel that way, then some of these high-quality retailers are looking darned cheap at these levels," he said. "Ralph Lauren [(NYSE:<a href="https://www.benzinga.com/quote/RL"> RL</a>)] and the Gap [(NYSE:<a href="https://www.benzinga.com/quote/GAP/news"> GAP</a>)] are my faves right now." That may be surprising, considering that Cramer said the<a href="https://www.benzinga.com/content/44299286/3-retail-giants-react-to-tariffs-what-it-means-for-consumers"> retail sector</a> was in the "blast radius" of a trade war.
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
There may be a method to Cramer's madness. He acknowledged that the immediate effect of tariffs would be to drive prices up and slow consumer activity. That's normal anytime there is a sudden price increase for products that people have grown accustomed to getting for less. However, Cramer doesn't think the slowdown will last forever.
He said that the "tariff reign of terror is temporary," meaning consumers will either become accustomed to the elevated prices or that a settlement will be reached between President Trump and the countries he's targeted for tariffs. In either case, the retail sector would rebound, and any stocks that took a hit during the recession would also make a comeback.
Cramer explained his reasons for picking Gap and Ralph Lauren as potential buys during the downturn. He cited Gap's recent strong quarterly earnings report as evidence that the turnaround led by new CEO Richard Dickson is working. Cramer wasn't the only person impressed by Gap's performance. According to<a href="https://www.cnbc.com/2025/03/06/gap-ceo-unpacks-blowout-quarter-the-progress-is-real.html"> CNBC</a>, the company's stock jumped by 17% in overnight trading after the company's March<a href="https://www.benzinga.com/quote/GAP/earnings"> earnings release</a>.
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
The report shows Gap exceeded analysts' earnings per share expectations by 42% and outpaces revenue expectation by 1.94% with a $4.15 billion quarter. Dickson said Gap's supply chain will only be minimally affected by Trump's tariffs because it sources less than 10% of its products from China and less than 1% from Mexico and Canada, the three nations that Trump's retail tariffs are currently targeting. Gap is also paying a 3.09% dividend.
Cramer's other retail pick, Ralph Lauren, is also coming off a strong quarterly<a href="https://www.benzinga.com/quote/RL/earnings"> earnings report</a>. The company's $4.82 earnings per share beat expectations by 6.40%, and its $2.14 billion in revenue bested the analysts' predictions by 6.67%. However, Cramer sees other factors playing in Ralph Lauren's favor. He believes the company's history as an upmarket brand and a symbol of high living will give it additional staying power.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Both factors translate into a wealthier client base than many other retailers, and consumers in that economic strata will be less deterred by a temporary price increase. That's why Cramer thinks Ralph Lauren will be among the companies at the leading edge of the rebound once retail bounces back. It doesn't hurt that<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44378283/ralph-laurens-prospects-of-market-share-gains-margin-expansion-turns-this-analyst-bullish"> Ralph Lauren shareholders</a> can earn a 1.44% dividend on the company&#8217;s $225.16 share price while waiting for the turnaround.
Cramer did add one big caveat to his bullish predictions on both stocks. He admitted he doesn't know how long you might have to hold them before the turnaround starts. "If you buy them and the president basically assures you that the forecast is pain, there's not much you can do short term. But longer term, you will do fine – I just can't predict when longer term starts," he said.&nbsp;
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Jim Cramer Says These Retail Stocks RL, GAP Can Survive A Market Correction

HC Wainwright &amp; Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy and raises the price target from $39 to $40.

AVBP

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $40

Gold is trading lower in possible reaction to US-China trade progress, which could ease macro concerns.

Maxim Group analyst Jason McCarthy downgrades Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) from Buy to Hold.

Downgrades

CLRB

Maxim Group Downgrades Cellectar Biosciences to Hold

Roth MKM analyst Suji Desilva maintains Pixelworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) with a Buy and lowers the price target from $2 to $1.

PXLW

Roth MKM Maintains Buy on Pixelworks, Lowers Price Target to $1

Bluebird Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) shares are trading higher on Wednesday following the news that Bluebird Bio, Carlyle, and SK Capital Partners, LP, have amended their definitive agreement.
Under the terms of the amended agreement, Bluebird stockholders can elect to receive either the original offer of $3.00 per share in cash plus a contingent value right (CVR) of $6.84 per share in cash payable upon achievement of a net sales milestone or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45404624/carlyle-sk-capital-partners-and-bluebird-bio-amend-merger-agreement" rel="noreferrer noopener">$5.00 per share in cash</a>.
The amended offer price provides an alternative for stockholders who would prefer greater upfront cash consideration instead of the potential <a target="_blank" href="https://www.benzinga.com/25/02/43880289/bluebird-bio-to-be-acquired-by-carlyle-group-sk-capital-former-mirati-therapeutics-ceo-set-to-lead-post-deal" rel="noreferrer noopener">upside of the CVR</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44651650/deal-dispatch-us-ma-is-quiet-but-abroad-volume-is-spiking" rel="noreferrer noopener">Deal Dispatch: US M&amp;A Is Quiet, But Abroad? Volume Is Spiking</a>
Any shares tendered for which no election is made will receive the original consideration of $3.00 per share in cash and a contingent value right per share.
In May, Carlyle and SK Capital received all required regulatory approvals to complete the transaction, and all parties expect the transaction to be consummated promptly following the successful completion of the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45206000/carlyle-and-sk-capital-receive-all-required-regulatory-approvals-to-complete-the-acquisition-of-bl" rel="noreferrer noopener">ongoing tender offer</a>.
In March, Bluebird received an unsolicited, non-binding written proposal from Ayrmid Ltd. Ayrmid proposed to acquire Bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achieving a&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44564776/gene-therapy-focused-bluebird-bio-receives-rival-takeover-offer-stock-jumps" rel="noreferrer noopener">net sales milestone</a>.
In April, the company said that after three weeks of engagement, including a timeline extension, Ayrmid did not submit a binding proposal to acquire Bluebird and had not obtained the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44835630/bluebird-bio-confirms-that-ayrmid-ltd-has-not-delivered-a-binding-offer-or-obtained-necessary-fina" rel="noreferrer noopener">necessary financing</a>.
Price Action: BLUE stock is up 50.3% to $4.98 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45409509/samsungs-1-7-billion-cooling-spree-buys-flaktgroup-to-target-data-center-boom" target="_blank" rel="noreferrer noopener">Samsung&#8217;s $1.7 Billion Cooling Spree &#8211; Buys FläktGroup To Target Data Center Boom</a></li>
</ul>
Image by Gumbariya via Shutterstock

Biotech

Health Care

Movers

General

BLUE

Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity

Roth Capital analyst Taz Koujalgi reiterates CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Buy and maintains $415 price target.

Reiteration

CYBR

Roth Capital Reiterates Buy on CyberArk Software, Maintains $415 Price Target

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45372571/anthony-scaramucci-says-bitcoin-is-evolving-from-a-tech-asset-to-digital-gold">extreme volatility</a> makes it unsuitable as a benchmark for liquid funds, according to a new report from RedStone Oracles.
What Happened: Authored by Marcin Kaźmierczak, the report argues that while Bitcoin has delivered headline-grabbing returns, its risk-adjusted performance disqualifies it as a standard for measuring the success of capital preservation strategies.
The analysis shows that Bitcoin's Sharpe ratio ranged from -6.58 to 6.97, and 25% of observations fell below -1.20, metrics that signal high capital risk and inconsistency.
These traits contradict the core objectives of liquid funds, which prioritize stability, capital efficiency and liquidity.
&#8220;Volatility, risk appetite, and investment horizons reveal why benchmarking every fund to the Bitcoin performance is fundamentally flawed,&#8221; Kaźmierczak wrote, noting that return rates alone offer a dangerously incomplete picture.
Even when compared to growth-oriented traditional indices like the S&amp;P 500, which itself may be too volatile for many liquid fund mandates, Bitcoin underperforms in terms of stability. 
The report notes that Bitcoin saw a -49.22% drawdown between January and September 2024, while the S&amp;P 500&#8217;s largest decline during the same period was -15.59%.
The standard deviation of Bitcoin's Sharpe ratio, calculated at 2.72, highlights frequent oscillations between extreme gains and severe losses.
These sharp swings, the report argues, expose portfolios to unacceptable downside risk, especially for funds with short-term liquidity requirements.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45409339/jpmorgan-completes-first-public-trade-of-tokenized-treasuries">JPMorgan Completes First Public Trade Of Tokenized Treasuries</a>
Why It Matters: Kaźmierczak also emphasizes the difference in performance evaluation frameworks now emerging in on-chain finance.
Platforms like Morpho and Euler are enabling fund managers to structure "vaults" that optimize for liquidity, yield, and risk.
While returns from these platforms may trail simple BTC holding strategies, they represent a more sustainable approach by adopting professional-grade risk frameworks.
By using 30-day rolling Sharpe ratios and controlling for trading days, the report builds a time-synchronized performance model, underscoring the need to consider risk-adjusted returns rather than chasing linear growth metrics.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45405649/the-curious-story-behind-the-melania-trump-meme-coin-launch">The Curious Story Behind The Melania Trump Meme Coin Launch</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin's Volatility Makes It Unfit As A Benchmark For Liquid Funds: Report

Ladenburg Thalmann analyst Mickey Schleien downgrades Gladstone Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIN#NASDAQ">GAIN</a>) from Buy to Neutral.

GAIN

Ladenburg Thalmann Downgrades Gladstone Inv to Neutral

Roth MKM analyst Richard Baldry reiterates SoundThinking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSTI#NASDAQ">SSTI</a>) with a Buy and maintains $30 price target.

SSTI

Roth MKM Reiterates Buy on SoundThinking, Maintains $30 Price Target

HC Wainwright &amp; Co. analyst Robert Burns maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Buy and lowers the price target from $145 to $134.

BNTX

HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $134

Lake Street analyst Thomas Flaten maintains Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) with a Buy and lowers the price target from $3 to $2.

Lake Street Maintains Buy on Biodesix, Lowers Price Target to $2

Roth MKM analyst Chip Moore reiterates EnerSys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENS#NYSE">ENS</a>) with a Buy and maintains $120 price target.

Roth MKM Reiterates Buy on EnerSys, Maintains $120 Price Target

Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) has <a target="_blank" href="https://www.benzinga.com/topic/autonomous-driving" rel="noreferrer noopener">confidentially filed for</a> a Hong Kong initial public offering to help raise capital to expand its business.
The autonomous-driving company filed for listing to limit the impact on Pony AI&#8217;s U.S.-traded shares, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-05-14/pony-ai-is-said-to-confidentially-file-for-hong-kong-listing?srnd=indus&amp;sref=TBDibEcD" rel="noreferrer noopener">reported</a> Wednesday, citing unnamed sources familiar with the matter.
The stock price soared in Wednesday&#8217;s premarket session before giving up the gains.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/04/45013465/pony-ai-and-tencent-partner-on-l4-robotaxis-expand-chinas-self-driving-future" rel="noreferrer noopener">Pony.ai And Tencent Partner On L4 Robotaxis, Expand China&#8217;s Self-Driving Future</a>
A&nbsp;Pony AI&#8217;s robotaxi caught ablaze for the first time on Tuesday, CNBC <a target="_blank" href="https://www.cnbc.com/2025/05/14/chinese-robotaxi-operator-ponyai-reports-first-fire-no-injuries.html" rel="noreferrer noopener">reported</a> on Wednesday, citing the company. No passengers were on board during the incident, and the vehicle automatically initiated an emergency stop, resulting in no collisions or injuries.
Pony AI told CNBC that it detected one of its fully self-driving vehicles as having an abnormal status in Beijing around 9:30 a.m. local time on May 13.
The company&nbsp;had raised&nbsp;~$413 million in a U.S. initial public offering and concurrent private placements in November 2024.
Pony AI stock surged 50% in the last 12 months. In April, Pony AI chief technology officer&nbsp;Lou Tiancheng told&nbsp;The Wall Street Journal&nbsp;that the company is <a target="_blank" href="https://www.benzinga.com/news/global/25/04/45049945/pony-ai-stock-is-galloping-higher-monday-heres-what-investors-are-watching" rel="noreferrer noopener">getting closer to</a> breakeven following cost-cutting measures.
Following the release of three new robotaxis at the Shanghai Auto Show last week,&nbsp;company executives reportedly said Pony AI could build its most advanced autonomous driving systems for 70% less than before.
Analysts said that Pony AI could reach single-unit breakeven goals by the end of 2025.
Reportedly, Pony AI plans to commercialize its robotaxis by mid-2025 and is targeting to add 700 vehicles to its fleet by the end of the year.
Last week, Pony AI tapped Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>)&nbsp;to <a target="_blank" href="https://www.benzinga.com/25/05/45225030/robotaxis-take-the-wheel-pony-ai-and-uber-team-up-for-international-rollout" rel="noreferrer noopener">launch robotaxi services</a> in the Middle East.
Price Action: PONY stock is down 8.08% to $16.50 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45325248/lyft-is-executing-well-but-analysts-caution-about-uber-and-waymo-competition" target="_blank" rel="noreferrer noopener">Lyft Is Executing Well But Analysts Caution About Uber And Waymo Competition</a></li>
</ul>
Photo by Tada Images via Shutterstock

Asia

Emerging Markets

IPOs

Tech

Media

PONY

UBER

Robotaxi Service Pony AI Stock Falls Despite IPO Buzz - Here's Why

Roth MKM analyst Jeff Martin maintains Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) with a Buy and lowers the price target from $6 to $5.

TACT

Roth MKM Maintains Buy on Transact Technologies, Lowers Price Target to $5

Lake Street analyst Eric Martinuzzi maintains SoundThinking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSTI#NASDAQ">SSTI</a>) with a Buy and raises the price target from $18 to $20.

Lake Street Maintains Buy on SoundThinking, Raises Price Target to $20

Press Releases

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Comments

Mineralys Therapeutics

Intérêt court

Mineralys Therapeutics (NASDAQ:MLYS) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL